Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (2)
  • Parasite
    (2)
  • Potassium Channel
    (2)
  • ROS Kinase
    (2)
  • SARS-CoV
    (2)
  • MAPK
    (1)
  • Opioid Receptor
    (1)
  • Reactive Oxygen Species
    (1)
  • TGF-beta/Smad
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

mink

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    6
    TargetMol | Inhibitors_Agonists
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Antibody Products
    5
    TargetMol | Antibody_Products
BMS986260
T87302001559-19-7
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM).
  • $80
In Stock
Size
QTY
Riminkefon
T698512168572-99-2
Riminkefon is a kappa opioid receptor agonist.
  • $2,570
10-14 weeks
Size
QTY
Mefloquine hydrochloride
Mefloquine HCl, Mefloquin hydrochloride
T086051773-92-3
Mefloquine hydrochloride (Mefloquin hydrochloride) is a quinoline derivative used for the prevention and therapy of P. falciparum malaria.
  • $30
In Stock
Size
QTY
Mefloquine
WR 142490, Ro-215998, Ro215998, Ro 215998, Lariam
T0860L53230-10-7
Mefloquine (Ro 215998), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus, and cancer research.
  • $64
In Stock
Size
QTY
PF-06260933 HCl
PF-06260933 dihydrochloride, PF06260933 dihydrochloride, PF 06260933 dihydrochloride
T339451883548-86-4
PF-06260933 Dihydrochloride is a MAP4K4 (HGK) inhibitor (IC50 = 140 nM). It can improve the fasting hyperglycemia in mice. In addition, it inhibited Mink and Tnik (IC50 values of 8 and 13 nM, respectively).
  • $816
35 days
Size
QTY
PF 06260933 dihydrochloride
T36016
MAP4K4 (HGK) inhibitor (IC50 = 140 nM). Also inhibits MINK and TNIK (IC50 values are 8 and 13 nM, respectively). Improves fasting hyperglycemia in mice. Orally active. Ammirati et al (2015) Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment. ACS Med.Chem.Lett. 6 1128 PMID:26617966
  • $271
Backorder
Size
QTY